Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61

Kazuhiko Kurozumi, Jayson Hardcastle, Roopa Thakur, Joshua Shroll, Michal Nowicki, Akihiro Otsuki, E. Antonio Chiocca, Balveen Kaur

Research output: Contribution to journalArticlepeer-review

61 Citations (Scopus)


Oncolytic viral therapy is under evaluation for toxicity and efficacy in clinical trials relating to several different tumors. We report a significant increase in the angiogenic index of oncolytic virus (OV)-treated glioma-matrigel implants (2.83-fold, P < 0.02). In a rat intracranial glioma model, large tumors from OV-treated animals were significantly more angiogenic than the phosphate-buffered saline (PBS)-treated control tumors (OV: 101 ± 21.6; PBS: 19.8 ± 10; P = 0.0037). Transcript profiling of OV-treated tumors revealed dysregulation of several transcripts involved in glioma angiogenesis. OV-mediated induction of CYR61 gene expression (8.94-fold, P = 0.001) correlated significantly with the presence of OV in tumor tissue in vivo (R = 0.7, P < 0.001). Further, induction of CYR61 mRNA and protein were confirmed in multiple human cancer cell lines and primary human tumor-derived cells in vitro, and in tumor lysate and cerebrospinal fluid (CSF) in vivo. Finally, we show that treatment of glioma cells with Cilengitide, known to counter CYR61-induced integrin activation, significantly suppressed the proangiogenic effect of OV treatment of gliomas (P < 0.05).

Original languageEnglish
Pages (from-to)1382-1391
Number of pages10
JournalMolecular Therapy
Issue number8
Publication statusPublished - Aug 2008
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61'. Together they form a unique fingerprint.

Cite this